DK151631B - Analogifremgangsmaade til fremstilling af 3,8-dialkylxantiner. - Google Patents

Analogifremgangsmaade til fremstilling af 3,8-dialkylxantiner. Download PDF

Info

Publication number
DK151631B
DK151631B DK168281AA DK168281A DK151631B DK 151631 B DK151631 B DK 151631B DK 168281A A DK168281A A DK 168281AA DK 168281 A DK168281 A DK 168281A DK 151631 B DK151631 B DK 151631B
Authority
DK
Denmark
Prior art keywords
ethyl
butyl
propyl
compound
compounds
Prior art date
Application number
DK168281AA
Other languages
Danish (da)
English (en)
Other versions
DK168281A (da
Inventor
Per Gunnar Kjellin
Carl Goeran August Persson
Original Assignee
Draco Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Draco Ab filed Critical Draco Ab
Publication of DK168281A publication Critical patent/DK168281A/da
Publication of DK151631B publication Critical patent/DK151631B/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK168281AA 1980-04-18 1981-04-14 Analogifremgangsmaade til fremstilling af 3,8-dialkylxantiner. DK151631B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8002910 1980-04-18
SE8002910A SE8002910L (sv) 1980-04-18 1980-04-18 3,8-dialkylxantiner, forfarande for deras framstellning, beredning och metoder for behandling av kronisk obstruktiv luftvegssjukdom och kardiovaskulera sjukdomar

Publications (2)

Publication Number Publication Date
DK168281A DK168281A (da) 1981-10-19
DK151631B true DK151631B (da) 1987-12-21

Family

ID=20340763

Family Applications (1)

Application Number Title Priority Date Filing Date
DK168281AA DK151631B (da) 1980-04-18 1981-04-14 Analogifremgangsmaade til fremstilling af 3,8-dialkylxantiner.

Country Status (21)

Country Link
US (1) US4546182A (fr)
EP (1) EP0038784B1 (fr)
JP (1) JPS56166191A (fr)
AT (1) ATE10099T1 (fr)
AU (1) AU543122B2 (fr)
CA (1) CA1156229A (fr)
DD (1) DD158400A5 (fr)
DE (1) DE3166893D1 (fr)
DK (1) DK151631B (fr)
ES (1) ES8203088A1 (fr)
FI (1) FI69465C (fr)
GR (1) GR82347B (fr)
HU (1) HU185254B (fr)
IE (1) IE51106B1 (fr)
NO (1) NO811161L (fr)
NZ (1) NZ196829A (fr)
PH (1) PH16264A (fr)
PL (1) PL134762B1 (fr)
PT (1) PT72881B (fr)
SE (1) SE8002910L (fr)
ZA (1) ZA811729B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810947L (sv) * 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
US4710503A (en) * 1985-02-07 1987-12-01 Euroceltique S.A. 6-thioxanthine derivatives
GB8618931D0 (en) * 1986-08-02 1986-09-10 Euro Celtique Sa 6-thioxanthines
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
JP2843634B2 (ja) * 1989-03-06 1999-01-06 協和醗酵工業株式会社 キサンチン誘導体
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
WO1990012797A1 (fr) * 1989-04-19 1990-11-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Derives de xanthene contenant du soufre comme antagonistes d'adenosine
CA2030112A1 (fr) * 1989-11-24 1991-05-25 Yasuo Ito Compose de xanthine, methode de preparation et composition pharmaceutique contenant ledit compose
US5366977A (en) * 1992-09-29 1994-11-22 The United States Of America, As Represented By The Department Of Health And Human Services Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipropylxanthine or xanthine amino congeners
DE4311538C1 (de) * 1993-04-07 1994-10-06 Boehringer Ingelheim Kg Verfahren zur Herstellung von 1,3-Dimethyl-4,5-diaminouracil
WO1994025462A1 (fr) * 1993-05-03 1994-11-10 The United States Of America, Represented By The Derives de 1,3,7-trialkyl-xanthine substitues en position 8 utiles comme antagonistes de recepteurs d'adenosine a2 a selectivite
US6316423B1 (en) 1996-04-10 2001-11-13 The United States Of America As Represented By The Departmant Of Health And Human Services Method of treating ischemic, hypoxic and anoxic brain damage

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53890B2 (fr) * 1972-04-22 1978-01-12
CA1077932A (fr) * 1976-03-31 1980-05-20 Berlex Laboratories, Inc. Composes de la xanthine pour le traitement des bronchospasmes et des affections allergiques
SE416810C (sv) * 1977-10-14 1982-07-19 Draco Ab Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
SE7810947L (sv) * 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents

Also Published As

Publication number Publication date
NO811161L (no) 1981-10-19
AU6955581A (en) 1981-10-22
PL134762B1 (en) 1985-09-30
PL230737A1 (fr) 1982-03-29
JPS56166191A (en) 1981-12-21
ES501400A0 (es) 1982-02-16
NZ196829A (en) 1984-12-14
DE3166893D1 (en) 1984-12-06
PT72881A (en) 1981-05-01
HU185254B (en) 1984-12-28
IE51106B1 (en) 1986-10-01
EP0038784B1 (fr) 1984-10-31
DD158400A5 (de) 1983-01-12
PT72881B (en) 1983-03-29
EP0038784A2 (fr) 1981-10-28
ES8203088A1 (es) 1982-02-16
GR82347B (fr) 1984-12-13
AU543122B2 (en) 1985-04-04
PH16264A (en) 1983-08-23
SE8002910L (sv) 1981-10-19
FI811212L (fi) 1981-10-19
EP0038784A3 (en) 1982-01-20
FI69465C (fi) 1986-02-10
DK168281A (da) 1981-10-19
CA1156229A (fr) 1983-11-01
ZA811729B (en) 1982-04-28
FI69465B (fi) 1985-10-31
US4546182A (en) 1985-10-08
IE810796L (en) 1981-10-18
ATE10099T1 (de) 1984-11-15

Similar Documents

Publication Publication Date Title
EP0011609B1 (fr) Dérivés de xanthine et préparation pharmaceutique les contenant pour utilisation dans le traitement de maladies chroniques d'obstruction des voies respiratoires et de maladies cardiaques
EP0010531B1 (fr) Alcoyl-3-xanthines, procédés pour leur préparation et compositions utilisables dans le traitement de maladies chroniques des voies respiratoires et de maladies cardiaques
EP0435811B1 (fr) Dérivés de xanthine
FI66383C (fi) Foerfarande foer framstaellning av farmakologiskt aktiva xantinderivat
DK151631B (da) Analogifremgangsmaade til fremstilling af 3,8-dialkylxantiner.
DK161965B (da) 6-thioxanthiner og salte deraf samt deres fremstilling og anvendelse
JPS61178966A (ja) 新規1−(2−ピリジル)ピペラジン化合物、その製造方法及びその医薬への用途
JPH0222075B2 (fr)
WO1999062905A1 (fr) Derives de 8-phenylxanthine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase
IE780310L (en) Heterocyclopyrimidines
JPH05262770A (ja) 化学的製法
KR830001654B1 (ko) 만성장애 기도증과 심장병 치료를 위한 3-알킬 크산틴의 제조방법

Legal Events

Date Code Title Description
PHB Application deemed withdrawn due to non-payment or other reasons
B1 Patent granted (law 1993)